Tsu, Japan
Tsu, Japan

Mie University is a national university in Tsu, Mie, Japan. As with other 'national' universities, 'Miedai' has been a national university corporation since April 2004, when state-funded universities were partially privatised. In 2006, it was ranked 250th in the Times Higher Education Supplement list of the world's best universities.Mie University was founded on 31 May 1949 with two faculties: Liberal Arts and Agriculture. These gave way to the establishment's present composition of six faculties: Humanities, Medicine, Education, Bioresources, Engineering and Common Education - the latter dealing with cross-faculty courses such as English language teaching. Its 'Center for International Exchange' promotes international links and issues involving the global community.The institution is Mie's only 'national university', located in the city of Tsu in the Kansai region, within easy reach of Kyoto, Osaka and Nagoya. The campus is situated in the north-east of the city, close to the coast of Ise Bay. Though some students make use of nearby accommodation, larger numbers commute from the larger cities, as well as nearby towns such as Ise, Matsusaka and Toba. Wikipedia.


Time filter

Source Type

Patent
Sysmex Corporation and Mie University | Date: 2016-08-30

Disclosed is a method for analyzing a concentration state of a measurement target component in blood, the method including: obtaining a value regarding an amount of the measurement target component in a collection member in which tissue fluid has been accumulated in advance, the tissue fluid having been extracted for a predetermined extraction time period from an organism which had been subjected to a process for accelerating the extraction of the tissue fluid; obtaining a value of an area under a blood concentration time curve of the measurement target component on the basis of the value regarding the amount of the measurement target component; and calculating a value regarding a ratio of a time period during which a concentration of the measurement target component has exceeded a predetermined concentration relative to the extraction time period, on the basis of the value of the area under the blood concentration time curve.


Patent
Sysmex Corporation and Mie University | Date: 2017-03-08

Disclosed is a method for analyzing a concentration state of a measurement target component in blood, the method including: obtaining a value regarding an amount of the measurement target component in a collection member in which tissue fluid has been accumulated in advance, the tissue fluid having been extracted for a predetermined extraction time period from an organism which had been subjected to a process for accelerating the extraction of the tissue fluid; obtaining a value of an area under a blood concentration time curve of the measurement target component on the basis of the value regarding the amount of the measurement target component; and calculating a value regarding a ratio of a time period during which a concentration of the measurement target component has exceeded a predetermined concentration relative to the extraction time period, on the basis of the value of the area under the blood concentration time curve.


Grant
Agency: Cordis | Branch: H2020 | Program: RIA | Phase: NMBP-02-2016 | Award Amount: 7.69M | Year: 2017

The main objective of this proposal is to develop reliable GaN-based power devices and systems for high and medium power electronics targeting industrial and automotive applications and bringing the GaN power devices another step towards the wide usability in the energy saving environment to further tap the full potential which this new material brings along. This proposal addresses two subjects, one of which is medium power (till 10kW) GaN-on-Si based lateral HEMT structures, with special focus on high reliability, which is still a major blocking item to allow wide-spread market adoption. Hence, the impact of the GaN material quality, in combination with the device layout in view of long-term reliability will be addressed. The project aims an in-depth reliability study and qualification strategy development whereby the study of the impact of dislocations and other structural disturbances inside the materials on the long term device reliability will be specifically addressed. In addition, this proposal aims to demonstrate new device concepts with increased robustness and reliability, which will be realized, evaluated and tested thoroughly. This will demonstrate how it is possible to overcome the known limitations of the GaN on Silicon technology, like e.g. the vertical leakage, trapping phenomena and/or breakdown of lateral HEMTs. The current proposal also contains the development of novel device architecture (dual channel, substrate removal, e-mode), as well as the exploration of new material systems (Aluminum Nitride (Al-based) devices) which can also largely contribute to overcome drawbacks of the GaN on Si technology. The applicability of the novel GaN-on-Si concepts in form of an industrial inverter will be demonstrated finally, with the development of an innovative low inductance packaging system for power devices, making full benefits of the fast switching capability of GaN-based power devices.


Patent
Mie University and Otsuka Pharmaceutical Factory Inc. | Date: 2016-01-19

Provided is siRNA effective for the treatment of fibrosis and a pharmaceutical containing the siRNA.


Patent
Mie University and Kyoto University | Date: 2016-08-10

The purpose of the present invention is to provide an interepitope sequence that effectively induces antigen presentation of each epitopes in a long-chain peptide antigen having a plurality of epitopes. A vaccine for the purpose contains a long-chain peptide antigen having a plurality of epitopes, said vaccine being characterized in that a sequence between the individual epitopes is one sequence selected from the group consisting of two to ten consecutive tyrosines, two to ten consecutive threonines, two to ten consecutive alanines, two to ten consecutive histidines, two to ten consecutive glutamines and two to ten consecutive asparagines. It is preferred that the vaccine is one selected from the group consisting of an anticancer vaccine, an antibacterial vaccine and an antiviral vaccine. It is also preferred that the vaccine is at least one selected from the group consisting of a peptide vaccine, a DNA vaccine, an mRNA vaccine and a dendritic cell vaccine.


Patent
Sekisui Medical Co. and Mie University | Date: 2016-01-13

Provided is a rapid and simple method of detecting methylated DNA. The method of detecting methylated DNA includes the following steps of: (1) treating sample DNA with a hydrogen sulfite; (2) amplifying the sample DNA treated with the hydrogen sulfite by PCR; and (3) subjecting the resultant PCR amplification product to ion-exchange chromatography.


Oncogenic transformation requires unlimited self-renewal. Currently, it remains unclear whether a normal capacity for self-renewal is required for acquiring an aberrant self-renewal capacity. Our results in a new conditional transgenic mouse showed that a mixed lineage leukemia (MLL) fusion oncogene, MLL-ENL, at an endogenous-like expression level led to leukemic transformation selectively in a restricted subpopulation of hematopoietic stem cells (HSCs) through upregulation of promyelocytic leukemia zinc finger (Plzf). Interestingly, forced expression of Plzf itself immortalized HSCs and myeloid progenitors in vitro without upregulation of Hoxa9/Meis1, which are well-known targets of MLL fusion proteins, whereas its mutant lacking the BTB/POZ domain did not. In contrast, depletion of Plzf suppressed the MLL-fusion-induced leukemic transformation of HSCs in vitro and in vivo. Gene expression analyses of human clinical samples showed that a subtype of PLZF-high MLL-rearranged myeloid leukemia cells was closely associated with the gene expression signature of HSCs. These findings suggested that MLL fusion protein enhances the self-renewal potential of normal HSCs to develop leukemia, in part through a Plzf-driven self-renewal program.


Patent
Mie University | Date: 2016-02-03

A vital stain for observation under multiphoton laser microscopy, the vital stain comprising one or more edible dye compounds.


Patent
Mie University | Date: 2016-10-19

[Problem to be solved] To provide a transgenic (TG) non-human mammal expressing human matrix metalloproteinase 2 (hMMP2) in whole body tissues, and a model animal developing COPD. [Solution] The objective is solved by development of an hMMP2-expressing TG non-human mammal characterized by the inclusion of a promoter to induce gene expression, and by the expression of the whole hMMP2 gene region placed on the downstream of the promoter that can induce systemic expression of the gene. The promoter for gene expression is preferably abeta-actin promoter, and the non-human mammal is preferably a mouse. Chronic obstructive pulmonary disease (COPD) can be induced by exposing the TG non-human mammal to inhalation of cigarette smoke extract.


Patent
Takara Bio Inc. and Mie University | Date: 2016-06-15

Disclosed is a cell which can express a non-natural oligomeric protein, which has, introduced therein, a gene encoding an exogenous polypeptide corresponding to at least one endogenous polypeptide constituting a natural oligomeric protein, and in which the expression of the endogenous polypeptide is inhibited.

Loading Mie University collaborators
Loading Mie University collaborators